115 related articles for article (PubMed ID: 17135635)
1. Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital.
Lewis DA; Tann M; Kesler K; McCool A; Foster RS; Einhorn LH
J Clin Oncol; 2006 Dec; 24(34):e54-5. PubMed ID: 17135635
[No Abstract] [Full Text] [Related]
2. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
3. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
4. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
5. Re: The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma: S. Hinz, M. Schrader, C. Kempkensteffen, R. Bares, W. Brenner, S. Krege, C. Franzius, S. Kliesch, R. Heicappel, K. Miller and M. De Wit J Urol 2008; 179: 936-940.
Lawrentschuk N; Bolton DM
J Urol; 2008 Dec; 180(6):2718; author reply 2718. PubMed ID: 18951564
[No Abstract] [Full Text] [Related]
6. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
7. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma.
Warren GP; Einhorn LH
J Clin Oncol; 1995 Nov; 13(11):2784-8. PubMed ID: 7595739
[TBL] [Abstract][Full Text] [Related]
8. Can we rely on PET in the follow-up of advanced seminoma patients?
Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
[TBL] [Abstract][Full Text] [Related]
9. Postchemotherapy residual masses in advanced seminoma: current management and outcomes.
Quek ML; Simma-Chiang V; Stein JP; Pinski J; Quinn DI; Skinner DG
Expert Rev Anticancer Ther; 2005 Oct; 5(5):869-74. PubMed ID: 16221056
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
[TBL] [Abstract][Full Text] [Related]
11. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
Bachner M; Loriot Y; Gross-Goupil M; Zucali PA; Horwich A; Germa-Lluch JR; Kollmannsberger C; Stoiber F; Fléchon A; Oechsle K; Gillessen S; Oldenburg J; Cohn-Cedermark G; Daugaard G; Morelli F; Sella A; Harland S; Kerst M; Gampe J; Dittrich C; Fizazi K; De Santis M
Ann Oncol; 2012 Jan; 23(1):59-64. PubMed ID: 21460378
[TBL] [Abstract][Full Text] [Related]
12. PET-CT for the management of testicular seminoma patients with post-chemotherapy residual masses.
Corsi O; Rada G; Peña J
Medwave; 2019 May; 19(4):e7625. PubMed ID: 31075095
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
[TBL] [Abstract][Full Text] [Related]
14. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
15. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.
Bilen MA; Hariri H; Leon C; Guo CC; Kuban DA; Pisters LL; Tu SM
Clin Genitourin Cancer; 2014 Aug; 12(4):e147-50. PubMed ID: 24674785
[No Abstract] [Full Text] [Related]
16. [Surgery of residual masses after chemotherapy in patients with testicular cancer].
Fléchon A; Rivoire M; Berger N
Rev Prat; 2007 Feb; 57(4):389-98. PubMed ID: 17455741
[TBL] [Abstract][Full Text] [Related]
17. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
18. False-positive hypermetabolic lesions on post-treatment PET-CT after influenza vaccination.
Kim JE; Kim EK; Lee DH; Kim SW; Suh C; Lee JS
Korean J Intern Med; 2011 Jun; 26(2):210-2. PubMed ID: 21716913
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Albers P
Aktuelle Urol; 2017 Feb; 48(1):79-87. PubMed ID: 28403497
[No Abstract] [Full Text] [Related]
20. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
Onozawa M; Kawai K; Yamamoto T; Hinotsu S; Tsukamoto S; Hattori K; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2004 Jul; 11(7):535-41. PubMed ID: 15242364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]